Plcacebo is named as an intervention in 2 current clinical trials in our China and Israel registers. 2 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Jemincare (1). The most-studied condition is ADPKD (Autosomal Dominant Polycystic Kidney Disease).
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Trial of JMKX003142 in Participants With Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT06800651 · ClinicalTrials.gov ↗ · ADPKD (Autosomal Dominant Polycystic Kidney Disease)
|
Phase 2 | Recruiting | Jemincare | China |
|
Early Beta Blocker Administration in STEMI Patients With SCAI B Status
NCT06967194 · ClinicalTrials.gov ↗ · ST Segment Elevation Myocardial Infarction (STEMI), Cardiogenic Shock Post Myocardial Infarction
|
Not applicable | Recruiting | Tel-Aviv Sourasky Medical Center | Israel |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Jemincare | 1 |
| Tel-Aviv Sourasky Medical Center | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 1 | 1 |
| Clinical trials in Israel | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China and Israel registers name Plcacebo as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 1 with sites in China and 1 with sites in Israel. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Jemincare (1) and Tel-Aviv Sourasky Medical Center (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Plcacebo works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Plcacebo works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Plcacebo (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.